Abstract This work is the second part of a review on the role of free iron forms in cardiovascular diseases. Here, we stress on various aspects related to the iron form that are free of poorly chelated to iron biocarriers, as for example the NTBI (Non Transferrin Bound Iron). We report on problems relating the determination of such free iron forms and, after all, on their implications in cardiac diseases as well as in venous insufficiency.
Non-Transferrin Bound Iron
In the first part 1 of the review we outlined the role of free iron in vascular diseases. Actually, it is well known that most of the body's iron is bound to the protein and non-protein biomolecules (carriers) in order to render it bioavailable, so as to move it between the various compartments and overcoming the great toxicity that characterize the free iron, due to its ability to create organic bounds, generating oxidative and nitro-oxidative stress. The most relevant iron carrier is the transferrin, while the main iron deposit is the ferritin. In recent years great attention has been paied to the non-transferrin bound iron (NTBI), a form of free iron highly reactive. Such poorly chelated form of iron could play a role in a number of pathologies and cannot depend on a systemic overload condition of iron. This should lead to a reflection since, for example, even in a condition of iron-deficient anaemia it is possible to find such toxic forms of iron released by their transferrin and ferritin carriers.
The non-transferrin bound iron (NTBI) forms, also denote as non-protein bound iron (NPBI), are grouped in different chemical forms with different characteristics. The cytoplasmic labile iron pool (LIP) is involved in the regulation of the cytosolic iron regulatory proteins (IRP) 2 . Further evidences show that there exist unbound forms also for the copper (non-ceruloplasmin bound copper, NCBC), that are toxic and relevant in the pathogenesis of neurodegenerative 3, 4 and cardiovascular diseases as well as in the atherogenic process 5 . The term "Labile Iron Plasma, LIP" was coined by Greenberg and Wintrobe in 1946 6 . It was then modified by Jacob in 1977 in "Transient Iron Pool, TIP" 7 , while Kruszewski 8 refers to it as "Labile Iron Pool, LIP", that is, as the poorly chelated iron with low molecular weight that is able to rapidly cross the cells. Some authors 8, 9 have also used the term of "catalytic iron pool" to indicate these scarcely bound, highly reactive iron forms, able to set off oxidative stress. Chelation kinetics studies have shown these "iron free" forms starting from the chelators used and, in this way, a number of techniques have been describes, such as: -BDI: bleomycin detectable iron -DCI: desferrioxamina chelable iron, a term used by Breuer to indicate NTBI iron 11 -BPS: bathophenantroline-disulphonate, a chromogenic chelator detecting the free iron at 532 nm 12 In normal conditions, the transferrin is saturated with the iron about at 20-35% (20 µmol/L), and this represents the main non-Heme circulating iron form. However, the transferrin saturation can increase, ensuring in this way an effective chelating mechanism and neutralizing a possible increase in the iron amount. For this reason, in a healthy individual the circulating NTBI (Non Transferrin Bound Iron) is essentially absent, its plasmatic levels being less than 1 mol/L, hard to detect by the majority of actual lab methods 13 . In pathologic conditions due to iron overload, such as thalassemia, hemochromatosis etc. 14, 15 , a progressive increase in the free NTBI iron content also corresponds to an increased iron saturation of transferrin.
While this mechanism is intuitive and explicable 16 its contrary, that is, normal or little increased levels of transferrinic saturation and increased circulating free iron, is less easy to understand 17 .
For this reason the early studies on NTBI iron were mainly performed in iron overload conditions. Subsequently, and surprisingly, it has been pointed out that even in normal conditions (in absence of iron overload) a non-vanishing part of free NTBI iron can be present. Than, the obvious queston follows: "how it is possible to find iron in its free form even when a formidable chelator as the transferrin is present?" A number of possible answers have been proposed to the above question. However, they appear to be partial, due to the numerous aspects not clearly defined and still object of investigation.
We begin focusing on the following point. The main sources of iron in humans derive from two fundamental mechanisms: -a) the absorption by the intestinal mucosa (an exogenous food source); -b) the recovery of iron past the lysis of aged erythrocytes and the macrophage activity (an endogenous source). The average life of red cells is 120 days, During this time, they runs about 300, 400 Km and, once aged, they show ever more serious alterations, being eventually destroyed and their components recycled. In this way, the proteins are reused for different scopes, the iron is disassembled and reused by other cells to build red cells or any other molecules that require it. The released heme is degraded by the heme-oxygenase microsomal enzymatic system, that requires oxygen and NADPH and finally ends as bilirubin that enters the bowel and performs a function in the food digestion. The endogenous source of iron deriving from the previously described erythrolysis mechanisms is more relevant with respect to the exogenous one, as for the latter one the control and the absorption by the intestinal mucose is particularly selective and finely tuned.
As an example, in case of hemolitic anemia or of transfusion, the excess of erythrocyte lysis determines an increase of iron that binds its chelator, the transferrin, causing an increase of its saturation index and, at the same time, releasing a certain amount of free NTBI iron 18 . In different conditions, as for example in absence of transferrin, the circulating levels of NTBI iron can reach values of 20 µmol/L, while when the transferrin is present but in reduced quantity the previous values are, in general, less than 10 µmol/L 19 . It is well known that the iron is able to lead to an oxidative stress; on the other hand, the oxidative stress can release free NTBI iron from different sources like the "iron sulphur proteins", ferritin, hemoglobin, etc., as it has long been reported in the literature [20] [21] [22] [23] , and this observation should induce to reflection. In summary, the sources of free NTBI iron can be generated in different pathologic conditions in which to the availability of high level of iron but also when the levels of transferrin iron saturation are normal or low, as consequence of oxidative stress. In fact, during the oxidative stress, an amount of iron can also be released by stable sources (ferritin, heme), triggering a vicious circle 24, 25 .
In Table I we report some pathologic conditions in which circulating forms of free, unchelated iron are observed 26 
:
In Table I it can be noticed that the higher free iron concentrations are not revealed in the hereditary hemochromatosis, as it could be expected, but in the cancer in course of chemotherapy 27 . Due to its cation nature, the iron easily binds to anion substrates giving rise to a number of new chemical compounds grouped, as already stated, under the denomination of non transferrin bound iron (NTBI). To the best of present knowledge, among all these substances in which the iron is readily available, the most frequent and dangerous are exactly those generated by the cation iron, 
Modalities and problems related to NTBI iron determination
As previously discussed, it is clear that the NTBI iron forms that are not stably bound to carriers (transferrin, ferritin, heme, etc.) are numerous and probably not yet completely known. As a consequence, the methods used for their determination are correspondingly numerous and constantly updated. Basically, the techniques used are the following: -1-Inductive estimate or dosing, based on the use of glycopeptide antibiotics like the bleomycin used in oncology (10) (bleomycin detectable iron, BDI). In presence of iron, the bleomycin is able to degrade DNA, producing free radicals. By a complex method, introduced for the first time by Gutteridge et al. 33 , it is possible to dose the iron not bound to transferrin. -2-Dosing by the use of different chelator agents, followed by the separation and dosing of the iron by analytic techniques (HPLC, atomic absorption, spectroscopy, etc. 40, 41 . Despite a little preference for the fluorescence, an agreement has not yet reached towards the methods to be used as standard. In the last meeting 41 60 samples extracted from patients affected by systemic iron overload (hemochromatosis, thalassemia, transfusion patients, etc.) have been sent to five labs all over the world and ten different laboratory kits have been tested for the determination of iron NTBI and LIP, without reaching, as we already said, an unique view, with an exception to be noticed, that is, the transferrin saturation index, that revealed to be the parameter in the best correlation to the possible presence of circulating NTBI-LIP iron. These researches are obviously performed on patients affected by systemic iron overload, that is, with transferrin highly saturated by iron, and not in pathologies with normal transferrin saturation, though in the literature 42 the presence of NTBI-LIP has been pointed out also in these circumstances. The iron that is not stably bound to its main carrier (the transferrin) represents a challenge to the different anti-oxidative mechanisms. Such NTBI iron enhances the oxidative stress mainly through the already cited Fenton and Haber-Weiss reactions ( Figure 1 ): with an increase of the oxidative action via the different radicals that are produced (hydroxy, hydrogen peroxide, superoxide, hypoalose acids, etc.). 
Iron and free iron fraction in cardiovascular pathologies
One of the early remarks on the relation between iron and cardiovascular pathologies was made by Sullivan 43 on 1981. He pointed out how the lesser amount of iron deposits (ferritin, etc.) in menopause and post-menopausal women plays a protective role, as well as regular phlebotomy appears to do. Another randomized study shows, during an observation period of 5 years in a sample of 1931 subjects, the greater incidence (2.2 times) of myocardial infarction in patients with a ferritin level > 200 µg/l with respect to those with a level <200 µg/l. A different work 45 points out, during a period of 6.4 years in a sample of 99 men, that subjects with low values of the ratio transferrin plasmatic receptor (tfr)/ferritin (that means large iron deposits) present a risk of myocardial infarction 2-3 times higher with respect to subjects with a larger tfr/ferritin ratio ( Figure 2 ):
Figure 2 -Relation between transferrin plasmatic receptor/ ferritin ratio and iron storage.
Many works demonstrate the relation existing among iron and atherogenic progression.
In the famous Brunico study [i] , five-years long with a randomized sample of 125 men and 125 women age 40-79 years and a participation in the trial of 93.6%, a strong correlation between carotid asymptomatic atherosclerosis and iron deposits increase (particularly with a ferritin level >50 µg/L) is proven 46, 47 . In 48 it is proved that in patients with end stage renal disease receiving an iron supply, is observed a thickening of the intima in the common carotid larger than in subjects that did not receive such a supply. -A number of independent studies 49, 50 show that in blood donors to low iron deposits levels correspond a lesser incidence of cardiovascular pathologies. Another point worth of attention is that all agents which inhibit the dietary absorption of iron (polyphenols, soy, casein, whey, chicken egg albumen, etc.) affect non-HEME iron only. Furthermore, adding Calcium does not affect the absorption of neither HEME nor non-HEME 60 iron,
in spite of what has been reported during previous studies ( Figure 3 ). -According to some authors 61 exercising can in many ways play a major role in iron excretion. -Some studies show that there is a correlation between cardiovascular conditions and iron [62] [63] [64] [65] .
-
Very interesting experimental studies [66] [67] [68] show that adding NTBI iron to cultures of human endothelial cells increases the expression of VCAM 1 (Vascular Cell Adhesion Molecule, etc.) as well as leucocyte rolling and endothelial barrier damage. This phenomenon can be stopped by adding iron chelating agents (desferrioxiamine, dipirydyl) to the cultures of human endothelial cells 67 , as it is also confirmed by another study on endothelial cells in the human aorta 68 .
There are more studies confirming the correlation between iron and cardiovascular condition compared to those which deny it [68] [69] [70] [71] , and albeit scientists are still divided concerning this topic, it is necessary to highlight that many of the studies which refused this correlation have been carried out with inappropriate techniques and indicators.
More recent studies 72 verified that NTBI can play a major role in terms of cardio toxicity in myocardial infractions (STEMI: ST evaluation acute myocardial infraction), especially as far as MVO (Micro Vascular Obstructions) and HEM (Hemorrhage) are concerned, the latter being a source of NTBI. This study points out the close ties between NTBI, CK-MB and troponin; even though the number of patients was rather scarce, such a correlation will definitely be the object of more and more thorough studies.
The study FeAST highlights that even chronic obstructive arterial disease in lower limbs is correlated with iron 73 ; furthermore other randomized experiments point out that the mere phlebotomy significantly reduced the mortality rate (myocardial infraction, stroke) among patients suffering from chronic obstructive arterial disease in lower limbs 74 .
The cardiovascular toxicity of NTBI can be summed up as in Figure 4 .
In one of his most recent papers 75 , Brissot highlights that even though there is not yet full knowledge of every factor able to produce NTBI, a major role is played by the iron loss in the transferrin-ferritin, by a poor iron re-usage during the erythrocyte lysis and, even more alarmingly, by the condition of chronic oxidative stress.
Other authors 76, 77 highlight that NTBI is a valid marker as far as biological damage is concerned, and not only in iron overload syndromes.
The main factor which regulates the iron output of a cell is the ferroportin under the effect of plasma hepcidin; therefore, low levels of hepcidin can trigger high level of transferrin saturation and NTBI iron, which is easily absorbed by the cells. Nevertheless, it is important to remark that though the lack of iron is related to cardiovascular disease, the study ARIC 78 on anemic patients show that "virtue stands in the middle". The ratio of body iron concentration and risk of occurrence of cardiovascular condition is not linear; on the contrary, it can be described as a U-shaped curve 79 .
Recently

Iron, iron-free and atherosclerosis
Over the past 30-40 years many studies 5, 24, 42, 46, 48, 51, 62, 66, 67, 77, 78 highlighted how the iron mediated oxidative stress played a major role in the formation of the atherosclerosis, also recently mentioning the toxicity of hemoglobin-free (Hb-free) and its iron content derived from erythrocyte lysis 79 .
For years the iron-induced oxidative stress was considered to be the main pathogenic trigger of atherosclerosis. Today, however, it is known that the factors that trigger the formation of atheroma are many and complex 80 , as far as iron and NTBI are concerned.
Specifically, hydroxyl radicals oxidize lipids and proteins, causing endothelial dysfunctions, cell proliferation (activation of monocytes-macrophages), DNA and immune system damage.
The oxidation of the low density lipoprotein (LDL) is a focal point in the formation of atheroma.
The reactive oxygen species (ROS) can alter the triglyceride fatty acid chains, especially the unsaturated ones, cholesterol esters, and protein structures with formation of Malondialdehyde (MDA) peroxides or hydroxides, pentanes, etc., the oxidation output of the cholesterol, i.e. oxysterols deriving from phospholipids, the alteration of apolipoprotein into carbonyls or amino acids (cysteine, cysteine, histidine, etc.), the formation of lipids- Most of the studies on the LDL oxidation (Ox-LDL) reported in vitro experiments where pro-oxidizing agents, such as iron, were used. So far scientists are not certain that the LDL oxidation occurs mainly on arterial walls, even though this is almost always the case for patients suffering from diabetes or cardiovascular diseases 83 . Moreover, the LDL oxidation appears to be correlated to the rise of the Creactive protein (CRP) 84 .
It appears that the endothelial dysfunction triggers the cell adhesion molecule (I-CAM 1 or E-Selectine); as a result, the circulation monocytes are then divided in two groups, one composed by the monocytes trapped in the endothelium and the other one by the monocytes which flew through the sub-endothelial space. This grouping takes place under the effect of cytokines such as M-CSF (Macrophage Colony Stimulating Factors, produced by macrophages themselves), endothelium cells and T lymphocytes, macrophages, specifically macrophages M1 (pro-inflammatory) rather than M2 (anti-inflammatory) 84 .
Macrophages M1 express Ox-LDL receptors on their surface for Ox-LDL that, once absorbed, turn the macrophages into foam cells due to the accumulation of cholesterol esters, etc. This macrophage population would also be the cause of both the proliferation of smooth muscle cells that migrate towards the arterial endothelium, and of the atheroma instability due to the activation of metalloproteinase 1,3,9 (MMP 1-3-9) with hydrolysis of the collagen in the atheroma fibrous cap 85, 86 . M2 macrophages have opposite tasks compared to the M1, and are also able to trigger several metalloproteinase (MMP 9-12-13-14) that are important in the re-shaping of the atheroma. Compared to M1 macrophages, M2 macrophages have a lower iron concentration 87 . In addition, chelating substances, such as the lactoferrin, can play a protective role 88 ; furthermore, the M1 activation can be directly induced by iron 89 .
Another factor that has recently been studied is the red blood cells phagocytosis in hemorrhage areas, specifically in atheroma 90 . This phenomenon is an important factor determining iron accumulation in Mhem macrophages that have features similar to the M2 macrophages (protective) 91, 92 . These HEME filled macrophages also present high HMOX1 levels (heme oxygenase-1, an enzymatic form which, contrarily to HMOX2, is inducible) that can trigger M1 macrophages (pro-inflammatory).
The heme oxygenase is an oxidoreductase that catalyzes the transformation of the heme into biliverdin, carbon monoxide and iron. Thanks to the biliverdin reductase, the biliverdin is later on transformed into bilirubin. The iron released induces the expression of the intracellular apoferritin with iron sequestration from the ferritin and iron redox reduction, as a result of the protective effect of the ferritin.
The heme oxygenase appears to play a crucial role in the cellular iron metabolism regulation; furthermore, it is an enzyme that can be induced by many factors such as oxidative stress, inflammation, reperfusion, etc. It is worth being noted, however, that free heme can directly activate M1 macrophages by interacting with Toll-like receptors expressed by many cells (monocytes, macrophages, mast cells, etc.), TLR4 (Toll-like Receptor 4) and innate immunity cells. Contrarily to HMOX2, the enzyme HMOX1, (heme oxygenase 2) is an inducible stress enzyme and its oxidoreductase regulates vascular activity and prevents inflammation and formation of atheroma 93 .
As a matter of fact, HMOX1 polymorphism or deficiencies can be linked to the occurrence of many diseases, especially atherosclerosis, cardiovascular disease, etc. 94, 95 .
Another study 96 shows that the iron contained in the atheroma is a risk factor which can be modified as far as the formation of atheroma plaques is concerned.
Iron and free iron in the chronic venous insufficiency
In the advanced stages of chronic venous disease that can be considered as insufficiency (CEAP Classification: C3-6) 97, 98 after the occurrence of edema (venous edema, CEAP: C3) a progressive tissue dystrophy takes place, usually evolving to ulcers. This kind of dystrophy is named lipodermatosclerosis (LDS, CEAP: C4b) and it is characterized by the progressive accumulation of hemosiderin iron in dermis and hypodermis. Legs undergo a hyper pigment production and hardening transformation, known as "inverted champagne bottle leg". Lipodermatosclerosis was initially described in 1955 by Huriez as Hypodermitis sclerodermiformis 99 , and later on many other authors denoted this condition by different names (liposclerosis, sclerosing panniculitis, lipomembranous panniculitis associated to venous stasis, etc.). However, this condition is today known in the scientific literature with the name of Lipodermatosclerosis (LDS).
The inferior limbs' chronic venous stasis triggers ambulatory venous hypertension and, finally, ends up rising the transmural pressure, with the appearance of erythrocyte extravasation (extravascular hemolysis) [100] [101] [102] which is also cause of the local hemosiderosis 103 117 , which observed that the consistent iron hyper overload in the ulcerated tissues was about 10 to 15 times higher compared to the same area in the counter lateral limb.
The presence of hemosiderinuria 118 is later reported in advanced dystrophic-ulcerative stages of chronic venous insufficiencies and, later on, in other disorders such as lymphedema, connective tissue disease, but not in ischemic ulcers 119 .
Other authors 120 highlight that iron is present in the ulcer fluid taken from chronic ulcers in lower limbs, but not in that extracted from acute ulcers.
Further studies highlight the relation between tissue iron overload and venous ulcers and some HFE polymorphism (hemochromatosis gene) [121] [122] [123] [124] [125] and also provided therapy evidence by using topical chelating agents which fasten the venous ulcer healing process 126, 127 . Some authors 128 used the PIXE (Proton Induced X-ray Emission Spectroscopy) to highlight that the iron concentration rises with the evolution of the disease; in fact, the iron deposition rate is higher in incompetent veins compared to competent veins (surgically collected veins); this rate is statistically correlated to oxidative stress parameters and to the ratio intima-media. The conclusions of these studies are that the dosage of the PIXE iron can be correlated to the evolution of the insufficiency.
Ferritin and hemosiderin represent the main ways iron can sediment; they differ each other as follows:
hemosiderin is not water-soluble, but undergoes denaturation; -ferritin is water-soluble but is temperature resistant up to 75°C (167°F). Hemosiderin iron is stored in the internal part of the protein shell, especially in the form of ferric hydroxide (Fe(OH) 3 ) as a consequence of its degradation and lysosome polymerization 129 . Ferritin is normally the predominant way in which iron is stored in the tissues; hemosiderin, however, can become the predominant form in case of iron overload, causing biological damage 130 ( Figure 5 ).
In fact the hemosiderin, especially in acid conditions (inflammation, ischemia), can release iron enhancing oxidative stress. When these conditions occur, the hemosiderin can turn itself from iron chelating agent to an iron releasing agent in the form of sediment:
For example, iron can sediment due to erythrocyte extravasation (erytrhodiapedesis, hemolysis related causes, etc.) both in ferritin and hemosiderin ( Figure 6 ). Moreover, iron can be directly be mobilized by hemosiderin or ferritin [130] [131] [132] [133] [134] .
An interesting study on animals 135 was led by inducing skin iron overload in three different ways (HFE mutation i.e. hemochromatosis, dietary iron overload, direct iron injection); the results of the study highlight that the direct iron injection is the most harmful of the three.
Another study 136 highlights the direct correlation between the stage of skin exfoliation (dyskeratosis) and the level of iron in the skin. Yet another study analyses the toxic effects derived from iron overload in many diseases, including connective tissue disease (Lupus, rheumatoid arthritis) 137 and in the wound healing process.
Finally, a biopsy study 138 was led on many cases of lower limb dermatitis (lichenoid, tinea, chronic venous stasis, folliculitis, psoriasis, etc.) where the Gomori test was used to determine the iron levels in the tissues; the results of the test were positive in 42% of the cases, thus highlighting the role iron plays in many chronic inflammatory skin disease. 
Conclusions
Many authors studied the whole literature concerning the relation between iron accumulation and the increased occurrence of cardiovascular diseases 139 ; even though this topic is still under discussion, the new techniques in the dosage of free NTBI highlighted the role played by free hemoglobin and HMOX1 (heme oxygenase) in the regulation of the cellular iron and the inducing effect of some drugs on the HMOX1, such as statins, aspirin and more particularly lansoprazole, etc. 140, 141 , their protective effect in the vessel endothelium 142 and, lastly, the challenge of the chelating therapy in local siderosis 143 ; all of the abovementioned factors seem to corroborate the hypothesis that the iron overload is toxic in cardiovascular diseases.
Chronic venous insufficiency is an ideal case to be investigated by studying NTBI as the hemosiderin deposition is very consistent.
Endnotes
[i] Brunico (Bruneck) in the province of Bolzano (Bozen), Italy, at the border between Italy and Austria.
